PRL and neoplasm: First-line management of prolactinoma is with dopamine agonists (DA) and studies have shown that cabergoline (CAB) is more effective in lowering prolactin (PRL) levels, reducing tumor size, and has less adverse effects when compared to bromocriptine [5].